Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 11/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.42 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triphosphate SCHEMBL28074755 | 0.96 | P2RY6 (0.49) | P2RY6P2RY14P2RY2POLA1P2RY4 | |
| Phosphoric Acid SCHEMBL2176024 | 0.93 | SLC28A1 (0.45) | P2RY6P2RY14P2RY2P2RY4SLC28A1 | |
| Phosphoric Acid SCHEMBL607047 | 0.93 | SLC28A1 (0.45) | P2RY6P2RY14P2RY2P2RY4SLC28A1 | |
| SCHEMBL98410 | 0.91 | SLC28A1 (0.49) | P2RY6P2RY14P2RY2P2RY4SLC28A1 | |
| Hydrochloric Acid SCHEMBL10584588 | 0.90 | SLC28A1 (0.48) | P2RY6P2RY14P2RY2P2RY4SLC28A1 | |
| Water SCHEMBL27625510 | 0.90 | SLC28A1 (0.48) | P2RY6P2RY14P2RY2P2RY4SLC28A1 | |
| SCHEMBL2800175 | 0.86 | P2RY6 (0.58) | P2RY6P2RY14P2RY2POLA1P2RY4 | |
| Pyrophosphoric Acid SCHEMBL18486638 | 0.86 | P2RY6 (0.47) | P2RY6P2RY14P2RY2P2RY4SLC28A1 | |
| SCHEMBL2176031 | 0.86 | P2RY6 (0.47) | P2RY6P2RY14P2RY2POLA1P2RY4 | |
| SCHEMBL29408563 | 0.85 | P2RY6 (0.42) | P2RY6P2RY14P2RY2POLA1P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538151-B1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INST BIOMEDICAL RES (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2024-03-12 | — | — | US | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230051644-A1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2023-02-16 | — | — | US | disclosed |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| US-11453858-B2 | Human plasma-like medium | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4023299-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | Nucana PLC (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
| EP-3447061-B1 | PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHORAMIDATE DERIVATIVE OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-10993957-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20140057866-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2014-02-27 | — | — | US | disclosed |
| EP-2681227-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2 ' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | Nucana Biomed Limited (GB) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012117246-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2 ' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NUCANA BIOMED LIMITED (GB) | 2012-09-07 | — | — | WO | disclosed |
| EP-1885878-B1 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | DAKO DENMARK AS (DK) | 2010-08-11 | — | — | EP | disclosed |
| US-20100166848-A1 | LIPOSOMAL FORMULATIONS FOR TREATING CANCER | ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE (FR) | 2010-07-01 | — | — | US | disclosed |
| EP-2187868-A1 | LIPOSOMAL FORMULATIONS FOR TREATING CANCER | Université de la Méditerranée (FR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009034148-A1 | LIPOSOMAL FORMULATIONS FOR TREATING CANCER | UNIVERSITE DE LA MEDITERRANEE (FR) | 2009-03-19 | — | — | WO | disclosed |
| US-20090042187-A1 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | DAKO DENMARK APS (DK) | 2009-02-12 | — | — | US | disclosed |
| EP-1885878-A2 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | Dako Denmark A/S (DK) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006128463-A2 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | DAKO DENMARK A/S (DK) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | P2RY6 795/4885P2RY14 751/4885P2RY2 773/4885 |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | P2RY6 787/4885P2RY14 753/4885P2RY2 767/4885 |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | P2RY6 774/4885P2RY14 720/4885P2RY2 707/4885 |
| US-20090042187-A1 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | TP53, CD74, TSG101 | P2RY6 3731/4885P2RY14 4141/4885P2RY2 3861/4885 |
| US-10993957-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | P2RY6 851/4885P2RY14 789/4885P2RY2 870/4885 |
| US-20140057866-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | P2RY6 774/4885P2RY14 720/4885P2RY2 707/4885 |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | P2RY6 744/4885P2RY14 737/4885P2RY2 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.